Biotron Limited (AU:BIT) has released an update.
Biotron Limited has clarified that previous announcements mistakenly referred to ‘blood’ viral loads instead of ‘nasal’ viral loads in their SARS-CoV-2 study, stating this was a typographical error without material impact on the trial’s design. The company also revealed that the delay in the BIT225-012 study’s preliminary results was due to increased workload and a shortage of reagents at Thai laboratories, a situation that came to light during a September 2023 visit by Biotron staff. Biotron is implementing improved processes to avoid future errors in their releases.
For further insights into AU:BIT stock, check out TipRanks’ Stock Analysis page.
